Contact Us | Find An Expert

Find an Expert
a

The Waukesha Freeman (Waukesha, Wisconsin): Local Ophthalmologist Treats Former Kindergarten Teacher’s Glaucoma with Microscopic Stents

Sep 26, 2022 | Blog

“She was part of a team that taught me to read, sing, learn shapes and letters. It is really neat to [treat] somebody who has given me a lot of gifts, too.” – Dr. Jessica Schrieber on Sue Howard, her former kindergarten teacher

After managing her glaucoma with eye drops for several years, Sue Howard, 71, grew concerned that her vision was declining. She sought out her former kindergarten student, Dr. Jessica Schrieber of Medical Eye Associates, for help. Building trust with a caregiver is important to Sue, and with Dr. Schrieber, that trust was already there. Sue, who recalls her former student as kind and bubbly, instantly felt comfortable with Dr. Schrieber. So when Dr. Schrieber recommended that Sue be implanted with iStent inject® W during cataract surgery to help manage her glaucoma, she was immediately onboard. 

Sue was implanted with iStent inject® W in both eyes during cataract surgeries earlier this year. Since then, she has lowered her eye pressure and has been able to stop taking daily glaucoma medications. Sue is no longer worried about her losing vision due to her glaucoma. She’s also glad she was able to reconnect and share some memories with her former student after all these years. The next time she experiences any concerns with her vision, she knows just who to call. 

Sue and Dr. Schrieber recently spoke with The Waukesha Freeman to discuss Sue’s journey with glaucoma and the importance of seeking timely treatment. You can check out the full story here.

For more information on glaucoma or to read about similar experiences like Sue, visit our website.

Speak With a Physician About iStent Today

Help is right around the corner. Leading ophthalmologists across the country offer iStent® technology, including the most recently FDA-approved iStent inject® W, designed to help reduce intraocular pressure in patients undergoing concurrent cataract surgery. Find out if you are a candidate for iStent inject® W by speaking with a trained physician in your area today.

Locate an iStent inject® W physician near you: https://www.glaukos.com/contact-a-physician/

The results described on this site are based on data collected regarding short- and intermediate-term efficacy of treatment. Individual results are not guaranteed and may vary. For more information, visit: https://www.glaukos.com/important-safety-information/istent-inject-w/.

PM-US-1124 Rev 1

Hear from Others with Glaucoma

View Stories

Recent Blog Posts

Four Tips for Talking about Your Glaucoma Diagnosis

Four Tips for Talking about Your Glaucoma Diagnosis

Jun 6, 2022 |

Opening up about your glaucoma diagnosis is beneficial not only for your mental health but for your overall quality of life, as well. It can also help to provide you with much-needed support throughout your glaucoma journey. Check out our blog for some tips on how best to open up about your condition to your loved ones.

Debunking Five Common Glaucoma Myths!

Debunking Five Common Glaucoma Myths!

May 16, 2022 |

Over time, many myths surrounding glaucoma have emerged that people continue to believe today. However, these are just that – myths! To help clear up any confusion, we’re sharing the facts behind some common myths about glaucoma!

How You Can Stay Active with Glaucoma

How You Can Stay Active with Glaucoma

May 3, 2022 |

A glaucoma diagnosis can be overwhelming and unexpected, but it should not prevent you from living a fulfilled and active life. That’s why finding the right treatment option to manage your glaucoma is crucial. Navigating a new condition, especially one that potentially leads to blindness, can be concerning. In this blog, we’re sharing some “glaucoma-friendly” physical activities and a few others you may want to avoid. 

Stay Connected

Sign up to receive the latest information about glaucoma, new treatments, research findings and more!

Glaukos will use the information you provide on this form to be in touch with you.

Consent(Required)
This field is for validation purposes and should be left unchanged.

INDICATION FOR USE
The iStent inject® W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild-to-moderate primary open-angle glaucoma.

CONTRAINDICATIONS
The iStent inject® W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

WARNINGS
Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

MRI INFORMATION
The iStent inject® W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

PRECAUTIONS
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure (IOP). The safety and effectiveness of the iStent inject® W have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated intraocular pressure (IOP) > 24 mmHg or unmedicated intraocular pressure (IOP) < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents.

ADVERSE EVENTS
Common postoperative adverse events reported in the iStent inject® randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject® vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%).

CAUTION
Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

Text Optimizer
Share This